Bristol-Myers Squibb Company (BMY)

NYSE: BMY · USD

$63.6

-2.26 (-3.4%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-06 02:00 UTC. Latest published research analyzed 2026-05-10 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh BMY analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-10

Our latest published analysis: BMY rated Strong Buy

BMY is rated Strong Buy at $56.16 versus the reconciled fair value midpoint of $84.55, implying +50.55% upside/downside. Confidence is separately disclosed at 80/100.

Fair value (mid)

$84.6 / share

$68.9 – $101

Upside to FV

+50.5%

from $63.6

Confidence

80/100

Moat

6.5/10

Market cap	$114.7B
Revenue (ttm)	49.2B
Net income (ttm)	9.3B
EPS (ttm)	$4.54
Shares out	2B
P/E (trailing)	14.0x
P/E (forward)	9.1x
Dividend	$2.52 (3.96%)
Volume	14,105,792
Beta	0.22
Price target	$66.2	+4.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 49.2B
Net income (ttm): 9.3B
EPS (ttm): $4.54
P/E (trailing): 14.0x
P/E (forward): 9.1x
Market cap: $114.7B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$46.16B	$45.01B	$48.30B	$48.20B	+1.4%
Gross profit	$36.02B	$34.31B	$34.33B	$34.26B	-1.7%
Operating income	$9.10B	$8.20B	$5.89B	$13.72B	+14.7%
Net income	$6.33B	$8.03B	$-8.95B	$7.05B	+3.7%
EPS (diluted)	$2.95	$3.86	$-4.41	$3.46	+5.5%
EBITDA	$19.22B	$19.37B	$3.17B	$15.23B	-7.5%
R&D	$9.51B	$9.30B	$11.16B	$9.95B	+1.5%
SG&A	$7.81B	$7.77B	$8.41B	$7.27B	-2.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
BA	The Boeing Company	189.8B	88.4x	2.0x	-12.7%	+8.8%	+8.0%	Sell
CMCSA	Comcast Corporation	87.8B	8.0x	0.7x	8.1%	+2.8%	-14.9%	Strong Buy
CSX	CSX Corporation	94.7B	29.6x	6.5x	12.4%	+5.2%	+46.2%	Sell
ABBV	AbbVie Inc.	435.1B	69.6x	6.8x	17.7%	+3.7%	+28.7%	Hold
ABT	Abbott Laboratories	182.9B	34.2x	3.9x	7.5%	+3.0%	-16.8%	Strong Buy
AMGN	Amgen Inc.	220.5B	25.3x	5.8x	20.2%	+8.4%	+39.1%	Strong Buy

All BMY indicators

Market & fundamental data

Available fields

291

Groups with data

Currency

USD

Showing 291 of 291 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000014272
Company name	Bristol-Myers Squibb Company
Country	United States
Country code	US
Cusip	110122108
Employees	32,500
Employees Change	-1,600%
Employees Change Percent	-4.69
Enterprise value	$163.6B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Drug Manufacturers - General
Industry PE	31.52
Industry PE Fwd	17.48
Isin	US1101221083
Last refreshed	2026-08-06
Market cap	$130B
Market cap category	Large-Cap
Price	$63.63
Price currency	USD
Rev Per Employee	1,513,415.38x
Sector	Healthcare
Sector PE	48.37
Sector PE Fwd	22.55
Sic	2834
Symbol	BMY
Tags	pharmaceuticals
Website	https://www.bms.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.14%
EV Earnings	17.62x
EV Sales Forward	3.38x
EV/EBIT	13.96x
EV/EBITDA	10.98x
EV/FCF	14.3x
EV/Sales	3.33x
FCF yield	8.8%
Forward P/E	9.92x
P/B ratio	5.82x
P/E ratio	14.01x
P/S ratio	2.64x
PE Ratio10 Y	38.47x
PE Ratio3 Y	16.21x
PE Ratio5 Y	18.92x
PS Forward	2.69x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	23.83%
EBITDA Margin	30.29%
FCF margin	23.26%
Gross margin	71.66%
Gross Profit	$35.2B
Gross Profit Growth	-0.04%
Gross Profit Growth Q	3.92%
Gross Profit Growth3 Y	0.16%
Gross Profit Growth5 Y	-0.04%
Net Income	$9.3B
Net Income Growth	83.84%
Net Income Growth Q	153.21%
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth3 Y	5.24%
Pretax Margin	24.21%
Profit Margin	18.87%
Profit Per Employee	$285,600
Profitable Quarters	$9
Profitable Years	1
ROA	10.72
Roa5y	6.51
ROCE	16.99
ROE	46.6
Roe5y	13.18
ROIC	21.68
Roic5y	14.63

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	1.85%
Cagr15y	9.46%
Cagr1y	46.92%
Cagr20y	9.32%
Cagr3y	6.6%
Cagr5y	2.66%
Div CAGR10	5.21%
Div CAGR3	3.71%
Div CAGR5	5.51%
EPS Growth	82.74
EPS Growth Q	153.1
EPS Growth Quarters	4
EPS Growth Years	1
EPS Growth3 Y	6.51
FCF Growth	-21.53%
FCF Growth Q	-13.16%
FCF Growth3 Y	2.19%
FCF Growth5 Y	-0.43%
OCF Growth	-19.62%
OCF Growth Q	-13.38%
OCF Growth10 Y	25.24%
OCF Growth3 Y	2.56%
OCF Growth5 Y	0.44%
Revenue Growth	3.11x
Revenue Growth Q	5.74x
Revenue Growth Quarters	5x
Revenue Growth Years	0x
Revenue Growth3 Y	2.87x
Revenue Growth5 Y	2.08x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.54
Assets	$87.6B
Cash	$11.1B
Current Assets	$28.6B
Current Liabilities	$18.7B
Debt	$45.1B
Debt EBITDA	$3.02
Debt Equity	$2.02
Debt FCF	$3.94
Equity	$22.3B
Interest Coverage	6.8
Liabilities	$65.3B
Long Term Assets	$59.1B
Long Term Liabilities	$46.7B
Net Cash	$-33.6B
Net Cash By Market Cap	$-25.84
Net Debt EBITDA	$2.25
Net Debt Equity	$1.5
Net Debt FCF	$2.94
Tangible Book Value	$-16.8B
Tangible Book Value Per Share	$-8.23
WACC	4.84

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.53
Inventory Turnover	5.09
Net Working Capital	$87M
Quick ratio	1.29
Working Capital	$9.9B
Working Capital Turnover	$6.3

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.47%
Dividend Growth	2.03%
Dividend Growth Years	19%
Dividend per share	$2.52
Dividend Years	56
Dividend Yield	3.96%
Ex Div Date	2026-07-02
Last Dividend	$0.63
Payout Frequency	Quarterly
Payout Ratio	55.47%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	20.16%
1Y total return	46.88%
200-day SMA	55.89
3Y total return	21.14%
50-day SMA	58.47
50-day SMA vs 200-day SMA	50over200
5Y total return	14.02%
All Time High	81.44
All Time High Change	-21.86%
All Time High Date	2022-12-01
All Time Low	0.96
All Time Low Change	6,548.9%
All Time Low Date	1974-10-04
ATR	1.94
Beta	0.22
Beta1y	0.25
Beta2y	0.29
Ch YTD	17.96
High	65.41
High52	68.1
High52 Date	2026-08-03
High52ch	-6.56%
Low	63.26
Low52	42.52
Low52 Date	2025-10-29
Low52ch	49.65%
Ma50ch	8.83%
Premarket Change Percent	-1.43
Premarket Price	$64.95
Premarket Volume	178,013
Price vs 200-day SMA	13.85%
RSI	59.77
RSI Monthly	59.48
RSI Weekly	64.28
Sharpe ratio	1.4x
Sortino ratio	2.55
Total Return	3.49%
Tr YTD	21.95
Tr15y	287.94%
Tr1m	9.46%
Tr1w	0.84%
Tr3m	12.14%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	16
Analyst Price Target Top	$64.75
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.61
Earnings EPS Estimate Growth	10.27
Earnings Revenue Estimate	11,698,609,520x
Earnings Revenue Estimate Growth	-4.65x
Operating Income	$15.6B
Operating Income Growth	23.89
Operating Income Growth Q	8.06
Operating Income Growth3 Y	21.58
Operating Income Growth5 Y	13.64
Operating margin	31.79
Price target	$66.21
Price Target Change	$4.06
Price Target Change Top	$1.76

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,039,545,818%
Float Percent	99.84%
Net Borrowing	-6,487,000,000
Shares Insiders	0.05%
Shares Institutions	82.29%
Shares Out	2,042,714,656
Shares Qo Q	0.05%
Shares Yo Y	0.47%
Short Float	2.2%
Short Ratio	3.33
Short Shares	2.2

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$10.9B
Adjusted OCF	12,229,000,000
Average Volume	12,890,650.95x
Bv Per Share	10.92
CAPEX	$-1.3B
Ch10y	-15.52
Ch15y	134.1
Ch1m	9.46
Ch1w	0.84
Ch1y	40.15
Ch20y	179.7
Ch3m	10.89
Ch3y	5.19
Ch5y	-7.1
Ch6m	10.43
Change	-3.43%
Change From Open	-1.82
Close	65.89
Days Gap	-1.64
Depreciation Amortization	3,296,000,000
Dollar Volume	897,551,545
Earnings Date	2026-07-30
Earnings Time	bmo
EBIT	$11.7B
EBITDA	$14.9B
EPS	$4.54
F Score	7
FCF	$11.4B
FCF EV Yield	6.99x
FCF Per Share	$5.6
Financing CF	-11,709,000,000
Fiscal Year End	December
Founded	1,887
Goodwill	21,740,000,000
Graham Number	33.41653
Graham Upside	-47.48
Income Tax	$2.6B
Investing CF	-4,905,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-30
Last Report Date	2026-06-30
Last Split Date	1999-03-01
Last Split Type	Forward
Last10k Filing Date	2026-02-11
Lynch Fair Value	$23.81
Lynch Upside	-62.58
Ma150	58.29
Ma150ch	9.17%
Ma20	61.58
Ma20ch	3.33%
Net CF	-3,889,000,000
Next Earnings Date	2026-10-29
Open	64.81
Optionable	Yes
P FCF Ratio	11.36
P FCF Ratio SBC	11.94
P OCF Ratio	10.17
P OCF Ratio SBC	10.63
Payment Date	2026-08-03
Position In Range	17.21
Post Close	63.63
Postmarket Change Percent	0.1
Postmarket Price	$63.69
Ppne	9,277,000,000
Pre Close	65.89
Price Date	2026-08-05
Price EBITDA	$8.73
Relative Volume	1.09x
Revenue	49,186,000,000x
SBC By Revenue	1.12x
Share Based Comp	553,000,000
Tax By Revenue	5.36x
Tax Rate	22.12%
Tr20y	494.21%
Tr6m	12.83%
Us State	New Jersey
Views	441
Volume	14,105,792
Z Score	2.59

Frequently asked questions

About this BMY report

What is the latest published BMY stock rating?

Bristol-Myers Squibb Company is shown with strong buy in the latest published report, analyzed 2026-05-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BMY analysis?

The full latest published report, analyzed 2026-05-10, lives at /stocks/BMY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for BMY?

The latest published report analyzed 2026-05-10 frames BMY around USD 69 to USD 101. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the BMY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Bristol-Myers Squibb Company (BMY)

Coverage state: Latest published research available

Generate a fresh BMY analysis

Our latest published analysis: BMY rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · BMY

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All BMY indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on BMY

Frequently asked questions